Vertex completes $10.0 billion acquisition of Crinetics Pharmaceuticals
The merger closed September 1, 2026, converting Crinetics shares into $85.00 per share in cash and installing new leadership at the surviving subsidiary.
SEC filing
1 story
The merger closed September 1, 2026, converting Crinetics shares into $85.00 per share in cash and installing new leadership at the surviving subsidiary.
SEC filing